Search
WL-1002
go.drugbank.com/drugs/DB05346ExperimentalWL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
LC16M8
go.drugbank.com/drugs/DB05019InvestigationalLC16m8 is a next-generation, attenuated smallpox vaccine that is designed to have a better safety profile, yet be equally effective, compared to conventional smallpox vaccines. It is the only attenuated vaccine to be licensed for use in ...
Iohexol
go.drugbank.com/drugs/DB01362ApprovedInvestigationalIohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Dental Mesenchymal Pulp Stem Cells
go.drugbank.com/drugs/DB15737InvestigationalDPSCs have multiple properties, and express surface antigens like CD90, CD29, and CD105 but not CD14 or CD45. … They also express specific pluripotency markers like MYC and SOX2 which can be absent in other MSCs.
Florbetaben F-18
go.drugbank.com/drugs/DB09148ApprovedInvestigationalFlorbetaben is a fluorine-18 (18F)-labeled stilbene derivative used for Positron Emission Tomography (PET) imaging of the brain. This radioactive diagnostic drug is used for the non-invasive detection of the density of beta-amyloid plaqu...
AVX-001
go.drugbank.com/drugs/DB19194Investigationalinvestigation in clinical trial NCT05164393 (Phase I/iia Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK
Nifurtimox
go.drugbank.com/drugs/DB11820ApprovedInvestigational[L15366] Nifurtimox, developed by Bayer, is a nitrofuran antiprotozoal drug used in the treatment of Chagas disease. … Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas.
2G7
go.drugbank.com/drugs/DB18589Experimental2G7 is an anti-TGF-beta monoclonal antibody developed by Genentech.
Narsoplimab
go.drugbank.com/drugs/DB16418ApprovedInvestigational[A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults